Pro-angiogenic and anti-angiogenic hematopoietic progenitor cell populations
AssigneeIndiana University Research and Technology Corporation
InventorsJamie Case, Julie A. Mund, Myka L. Estes
Life of this patent
Estimating the term…
Abstract
Methods for identifying active angiogenesis and vasculopathy are described. More particularly, the present disclosure relates to cellular biomarkers, and to methods of screening cellular biomarkers for identifying active angiogenesis.
Claims20
A method for identifying active angiogenesis in a subject having or suspected of having cancer, the method comprising:
- obtaining a peripheral blood sample from the subject;
- determining a ratio of pro-angiogenic circulating hematopoietic stem and progenitor cells (pCHSPC) to anti-angiogenic circulating hematopoietic stem and progenitor cells (aCHSPC) for the peripheral blood sample;
- and
- identifying active angiogenesis in the subject if the ratio is greater than 2.0.
A method for identifying active angiogenesis in a subject having or suspected of having cancer, the method comprising:
- obtaining a bone marrow sample from the subject;
- determining a ratio of pro-angiogenic circulating hematopoietic stem and progenitor cells (pCHSPC) to anti-angiogenic circulating hematopoietic stem and progenitor cells (aCHSPC) for the bone marrow sample;
- and
- identifying active angiogenesis in the subject if the ratio is greater than 2.0.
A method of screening cellular biomarkers in a peripheral blood sample for identifying active angiogenesis in a subject having or suspected of having cancer, the method comprising:
- obtaining a peripheral blood sample from the subject;
- determining by multi-parametric flow cytometry a number of pro-angiogenic circulating hematopoietic stem and progenitor cells (pCHSPC) in the peripheral blood sample;
- determining by multi-parametric flow cytometry a number of anti-angiogenic circulating hematopoietic stem and progenitor cells (aCHSPC) in the peripheral blood sample;
- and
- calculating the ratio of pro-angiogenic circulating hematopoietic stem and progenitor cells (pCHSPC) to anti-angiogenic circulating hematopoietic stem and progenitor cells (aCHSPC);
- and
- identifying active angiogenesis in the subject if the ratio is greater than 1.8.
Dependencies are inferred from the claim text.